Midatech Pharma (MTPH)

Sector:

Pharma and Biotech

Index:

FTSE AIM All-Share

 2.40p
   
  • Change Today:
      0.000p
  • 52 Week High: 11.50
  • 52 Week Low: 2.30
  • Currency: UK Pounds
  • Shares Issued: 469.90m
  • Volume: 2,754,638
  • Market Cap: £11.28m
  • RiskGrade: 395
  • Beta: 0.02

Midatech Pharma doses first volunteers in acromegaly treatment study

By Duncan Ferris

Date: Tuesday 08 Oct 2019

LONDON (ShareCast) - (Sharecast News) - Midatech Pharma on Tuesday announced that its MTD201 Phase 1 study for the treatment of acromegaly and neuroendocrine tumours has commenced.
Half of the trial's 28 healthy volunteers were injected with a dose of Sandostatin 100 microgram/1 ml solution on 5 October before receiving a 30mg injection of MTD201 on Monday.

The remaining subjects will undergo the same procedures later this week to complete the dosing phase. Volunteers will then begin a 63-day observation and sampling period, after which the company said it expected data to be analysed and results released in late 2019 or early next year.

Acromegaly is a hormonal disorder that results in abnormal growth of bones, particularly in the hands, feet and face, while neuroendocrine tumours can also result in the production of excess hormones.

Midatech in September said the objective of the newly launched trial is to determine the administration route for a pivotal registration study to be commenced in 2020.

The company has previously tested MTD201 in a 2018 phase 1 exploratory study, after which it said the treatment had delivered favourably when compared to the market-leading alternative, Sandostatin LAR, with advantages including smaller needle sizes, simpler injection and quicker bedside reconstitution.

Midatech Pharma shares were up 2.20% at 6.26p at 1026 BST.

Email this article to a friend

or share it with one of these popular networks:


Note 1: Prices and trades are provided by Digital Look Corporate Solutions and are delayed by at least 15 minutes.

Note 2: RiskGrade figures are provided by RiskMetrics.

 

MTPH Market Data

Currency UK Pounds
Share Price 2.40p
Change Today 0.000p
% Change 0.00 %
52 Week High 11.50
52 Week Low 2.30
Volume 2,754,638
Shares Issued 469.90m
Market Cap £11.28m
Beta 0.02
RiskGrade 395

MTPH Star Ratings

Compare performance with the sector and the market.
more star ratings
Key: vs Market vs Sector
Value
22.58% above the market average22.58% above the market average22.58% above the market average22.58% above the market average22.58% above the market average
32.20% above the sector average32.20% above the sector average32.20% above the sector average32.20% above the sector average32.20% above the sector average
Price Trend
96.26% below the market average96.26% below the market average96.26% below the market average96.26% below the market average96.26% below the market average
89.83% below the sector average89.83% below the sector average89.83% below the sector average89.83% below the sector average89.83% below the sector average
Income Not Available
Growth
35.82% above the market average35.82% above the market average35.82% above the market average35.82% above the market average35.82% above the market average
36.84% above the sector average36.84% above the sector average36.84% above the sector average36.84% above the sector average36.84% above the sector average

MTPH Dividends

No dividends found

Trades for 09-Dec-2019

Time Volume / Share Price
16:26 50,000 @ 2.30p
16:19 14,876 @ 2.43p
16:19 50,000 @ 2.30p
15:20 30,000 @ 2.45p
14:02 28,383 @ 2.45p

MTPH Key Personnel

CEO Craig Cook
CFO Stephen Stamp

Top of Page